Survivors | Nonsurvivors | p-value | |
Subjects | |||
Male | 25 | 9 | |
Female | 4 | 7 | |
Age yrs | 63.2±17 | 58.4±19.3 | 0.367# |
APACHE II | 14.0 (12.0–15.0) | 12.0 (6.25–17.0) | 0.277# |
SOFA D1 | 3.0 (2.0–5.0) | 3.5 (3.0–7.0) | 0.220# |
CRP D1 | 16.50 (6.3–23.7) | 19.0 (13.9–28.5) | 0.088# |
PCT D1 | 0.34 (0.21–0.49) | 0.52 (0.45–2.24) | 0.001 |
SOFA D4 | 4.0 (3.0–6.0) | 8.0 (4.0–8.5) | 0.016 |
CRP D4 | 16.0 (10.8–29.5) | 16.7 (7.56–30.6) | 0.661# |
PCT D4 | 0.50 (0.41–1.26) | 0.45 (0.31–1.37) | 0.167# |
SOFA D7 | 3.0 (2.0–6.0) | 6.0 (2.75–9.0) | 0.169# |
CRP D7 | 16.8 (9.2–24.8) | 16.7 (8.3–38.4) | 0.456# |
PCT D7 | 0.42 (0.35–0.63) | 4.24 (0.96–12.1) | <0.001 |
Total duration of mechanical ventilation days | 45±29 | 29±20 | |
Duration of prior mechanical ventilation days | 10±7 | 12±10 | |
Duration of ICU stay days | 49±32 | 30±21 | |
Microbiological culture | |||
Endotracheal aspirate | 25 | 12 | |
Bronchoscopic material | 4 | 4 | |
Admission diagnosis | |||
Medical | 25 | 13 | |
Surgical | 4 | 3 | |
COPD–ARF | 11 | 3 | |
ARDS¶ | 5 | 5 | |
Trauma | 4 | 2 | |
ARF type II (obesity, OSAS) | 1 | 3 | |
Drug overdose | 3 | 0 | |
Bronchial asthma | 2 | 0 | |
Stroke/AMI | 0 | 2 | |
Guillain–Barré | 1 | 1 | |
Diabetic ketoacidosis | 2 | 0 |
Data are presented as n, mean±sd or median (interquartile range 25–75th percentile), unless stated otherwise. Values in bold are statistically significant. APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; CRP: C-reactive protein; PCT: procalcitonin; D: day; ICU: intensive care unit; COPD: chronic obstructive pulmonary disease; ARF: acute respiratory failure; ARDS: adult respiratory distress syndrome; OSAS: obstructive sleep apnoea syndrome; AMI: acute myocardial infarction. #: nonsignificant; ¶: acute pancreatitis (n = 3), multiple transfusions (n = 2), drug abuse (n = 2), near drowning (n = 1), inhalation of toxic gases (n = 1), lipid embolism (n = 1).